Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06173778 · ClinicalTrials.gov registry record · Phase 2
Semaglutide for Post-Smoking Cessation Weight Management
A Phase 2 study of Obesity and Overweight, sponsored by The University of Texas Health Science Center, Houston.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 197
- Enrollment target
- 2
- Study locations
NCT06173778 is a Phase 2 study of Obesity and Overweight that is actively recruiting participants, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 197 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (76% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06173778, a Phase 2 study of Obesity and Overweight, is actively recruiting participants, sponsored by The University of Texas Health Science Center, Houston.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 197 participants
- Enrollment target
- 2
- Study locations
Study Summary
This trial will examine the effect of semaglutide 2.4mg on changes in body weight, body composition, and peripheral and central mechanisms that control appetite, satiety, and food intake in the context of smoking cessation.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG semaglutide 2.4mg
- DRUG Nicotine Replacement Therapy (NRT, nicotine patch)
- BEHAVIORAL Brief Smoking Cessation Counseling
Study Locations (2)
Texas
- The University of Texas at Austin - Austin
- The University of Texas Health Science Center at Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 197 participants |
| Start Date | 2024-04-23 |
| Est. Completion | 2026-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06173778
The ClinicalTrials.gov registry entry for NCT06173778 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 197 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (76% lower). The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT06173778 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06173778 about?
NCT06173778 is a clinical study titled "Semaglutide for Post-Smoking Cessation Weight Management". This trial will examine the effect of semaglutide 2.4mg on changes in body weight, body composition, and peripheral and central mechanisms that control appetite, satiety, and food intake in the context of smoking cessation.
What is the current status of trial NCT06173778?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 197 participants. The study started on 2024-04-23. Estimated completion is 2026-08-01.
What conditions does trial NCT06173778 study?
This clinical trial studies the following conditions: Obesity, Overweight, Cigarette Smoking.
What interventions are being tested in trial NCT06173778?
The interventions under investigation include: Placebo (DRUG), semaglutide 2.4mg (DRUG), Nicotine Replacement Therapy (NRT, nicotine patch) (DRUG), Brief Smoking Cessation Counseling (BEHAVIORAL).
Who is sponsoring clinical trial NCT06173778?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06173778 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.